New evidence separates sensitive skin syndrome from rosacea condition

New research from the George Washington University School of Medicine and Health Sciences provides evidence that sensitive skin syndrome (SSS) is biologically distinct from rosacea, helping clarify a long-standing debate in dermatology and potentially guiding more targeted treatment approaches.

The pilot study, published in the Journal of the American Academy of Dermatology, examined whether hallmark drivers of rosacea - including Demodex mite overgrowth and heightened innate immune activity - also contribute to sensitive skin syndrome. Researchers found they do not.

Sensitive skin syndrome affects millions of people and is characterized by symptoms such as burning, stinging, itching, tingling, tightness, pain, and redness triggered by environmental, chemical, hormonal, or psychological factors. Because these symptoms overlap with rosacea, the two conditions are often confused clinically.

These findings further support our ongoing work that sensitive skin syndrome is a unique skin condition, not simply a milder form of rosacea, a condition well known for imparting skin sensitivity. This distinction matters because it can help clinicians avoid treatments that may not benefit sensitive skin patients and instead focus on over the counter and prescription therapies better aligned with the biology of the condition."

Adam Friedman, professor and chair of dermatology at GW and senior author of the study

The study included 30 women between the ages of 30 and 50, half with sensitive skin syndrome and half with non-sensitive skin. Researchers used advanced skin imaging to assess the presence of Demodex folliculorum mites and analyzed skin protein samples to measure levels of antimicrobial peptides linked to inflammation.

Key findings included:

• Demodex mites were present at the same rate in both sensitive skin and non-sensitive skin participants.

• Two antimicrobial peptides commonly elevated in rosacea - cathelicidin and dermcidin - were significantly reduced in participants with sensitive skin syndrome.

• The findings suggest that the inflammatory pathways central to rosacea may not drive sensitive skin syndrome.

"These results help provide biologic evidence that sensitive skin syndrome has its own unique mechanisms," said Nikita Menta, first author of the study and GW SMHS/Galderma Sensitive Skin Research Fellow. "Understanding those differences is important for developing more precise diagnostic and treatment strategies."

The authors note that additional research with larger patient populations is needed, but say the findings represent an important step toward defining sensitive skin syndrome as a standalone dermatologic condition.